<DOC>
	<DOCNO>NCT02896920</DOCNO>
	<brief_summary>This study assess Humira's速 real-life effectiveness management dermatological manifestation moderate severe Hidradenitis Suppurativa ( HS ) .</brief_summary>
	<brief_title>Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness Impact HS Burden Illness</brief_title>
	<detailed_description />
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Has clinical diagnosis moderate severe HS accord treat physician judgment Need change ongoing therapy reason , limited inadequate response , intolerance , suboptimal compliance , patient preference . Patient approach participate study decision change patient 's therapy Humira速 make treat physician . Has provide write informed consent ( Patient Authorization ) participation study Is participate clinical interventional study Was treat Humira速 , biologic agent HS prior baseline visit Has active skin disease condition , opinion treat physician , prohibits patient participate study obscures assessment treatment HS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Humira速</keyword>
	<keyword>Hidradenitis Suppurativa ( HS )</keyword>
	<keyword>Canada</keyword>
</DOC>